Semaglutide Cuts Body Weight by 15.1%: What the 2023 OASIS 1 Trial Means for You
TL;DR: Oral semaglutide 50 mg, taken once daily alongside lifestyle changes, reduced average body weight by 15.1% over 68 weeks in a rigorous phase 3 trial—making it one of the most effective non-surgical obesity treatments now available by prescription.
If you have spent years cycling through diets and exercise regimens without lasting results, a robust new clinical option has arrived. On August 26, 2023, The Lancet published the full results of the OASIS 1 trial, a randomised, double-blind, placebo-controlled phase 3 study led by Filip K. Knop and colleagues. Participants taking oral semaglutide 50 mg once daily lost an average of 15.1% of their body weight by week 68, versus just 2.4% in the placebo group—a difference that is both statistically and clinically significant. This single finding has reshaped the conversation around pharmacological weight management and signals a new era for the estimated 1 billion adults living with obesity worldwide.
What Is Semaglutide?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist—a class of drug that mimics the action of the GLP-1 hormone naturally released after eating. GLP-1 signals the brain to increase feelings of fullness, slows gastric emptying, and reduces appetite-driven food intake. The result is a sustained, physiologically supported reduction in calorie consumption rather than a willpower-dependent crash diet.
Novo Nordisk originally developed semaglutide as a treatment for type 2 diabetes under the brand name Ozempic (injectable) and Rybelsus (oral). The injectable formulation at higher doses was subsequently approved for chronic weight management as Wegovy. The OASIS 1 trial now establishes that a higher-dose oral formulation (50 mg) can rival injectable efficacy—a crucial finding because many patients prefer pills over weekly injections.
Inside the OASIS 1 Trial
Study Design
The OASIS 1 trial enrolled 667 adult participants across 50 outpatient clinics in nine countries. All participants had a baseline BMI of at least 30 kg/m² (obesity) or at least 27 kg/m² with at least one weight-related comorbidity, and none had type 2 diabetes. Participants were randomly assigned to receive either oral semaglutide 50 mg once daily or a matching placebo. Critically, every participant also received a standardised lifestyle intervention program covering dietary guidance, physical activity coaching, and behavioural support—underscoring that the drug works best as a complement to healthy habits, not a replacement.
According to the study published in The Lancet (Knop et al., DOI: 10.1016/s0140-6736(23)01185-6), the co-primary endpoints were percentage change in body weight from baseline and the proportion of participants achieving ≥5% weight loss by week 68.
Key Efficacy Results
| Outcome | Semaglutide 50 mg | Placebo |
|---|---|---|
| Mean body weight change | –15.1% | –2.4% |
| ≥5% weight loss | 85% of participants | 26% |
| ≥10% weight loss | 69% | 12% |
| ≥15% weight loss | 54% | 7% |
These numbers are striking. More than half of semaglutide users lost at least 15% of their starting weight—a threshold that clinicians associate with meaningful improvements in blood pressure, blood glucose, sleep apnoea severity, and joint load. The placebo group, receiving the same lifestyle programme, achieved only a fraction of these outcomes.
Safety Profile
No medication is free of side effects. In the OASIS 1 trial, gastrointestinal adverse events were the most common concern: approximately 92% of semaglutide participants reported at least one GI symptom, compared with roughly 65% in the placebo group. However, the vast majority of these events—nausea, vomiting, constipation, diarrhoea—were mild to moderate in severity and typically emerged during the dose-escalation phase before subsiding. Discontinuation due to adverse events occurred in about 13% of the semaglutide group versus 6% in placebo. No new safety signals emerged beyond those already known from injectable semaglutide.
Regulatory and Access Landscape
NICE Guidance (England)
In parallel with mounting clinical evidence, health technology bodies are formalising access. In March 2023, the UK's National Institute for Health and Care Excellence (NICE) issued guidance (TA875) recommending semaglutide for weight management within specialised NHS services, subject to a commercial access agreement with Novo Nordisk to monitor cost-effectiveness in real-world use. According to the NICE guidance (TA875), eligible patients must have a BMI of at least 35 kg/m² (or 32.5 kg/m² for certain high-risk ethnic groups) plus at least one weight-related comorbidity, and must be enrolled in a specialist weight management programme.
This access agreement is significant: it means tens of thousands of patients in England gain a structured pathway to semaglutide through the NHS rather than relying solely on private prescriptions, which can cost several hundred pounds per month.
United States and Beyond
In the United States, the FDA approved injectable semaglutide (Wegovy, 2.4 mg weekly) for chronic weight management in June 2021. The oral 50 mg formulation studied in OASIS 1 is not yet separately FDA-approved for obesity but represents an active regulatory frontier. Novo Nordisk has indicated plans to submit for approval, and the OASIS 1 data are widely expected to anchor that submission.
Who Is a Candidate for Semaglutide?
Semaglutide is a prescription-only medication and is not appropriate for everyone. Broadly, current guidelines point toward candidates who:
- Have a BMI ≥30 kg/m², or ≥27 kg/m² with a weight-related health condition (hypertension, type 2 diabetes, dyslipidaemia, obstructive sleep apnoea)
- Have not achieved adequate weight loss through sustained diet and exercise alone
- Do not have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (contraindications for GLP-1 agonists)
- Are not pregnant or planning pregnancy
Healthcare providers also consider cardiovascular history, kidney function, and concurrent medications before prescribing. A shared decision-making conversation with a physician or specialist is essential.
How Semaglutide Fits Into a Healthy Lifestyle Plan
One of the most important messages from the OASIS 1 data is that lifestyle intervention was a constant for both groups. The superior outcomes in the semaglutide arm emerged on top of dietary counselling and physical activity support—not instead of it. Practitioners and patients should view semaglutide as a pharmacological amplifier of healthy behaviours, not a shortcut.
Practical integration points:
- Diet: A moderate caloric deficit (300–500 kcal/day below maintenance) remains the dietary backbone. Semaglutide reduces appetite, making this deficit easier to sustain without hunger-driven lapses.
- Physical activity: Resistance training preserves lean muscle mass during rapid weight loss—a priority when losing 10–15% of body weight.
- Behavioural support: Cognitive behavioural techniques addressing emotional eating complement the drug's physiological satiety signals.
- Monitoring: Regular check-ins with a healthcare provider to assess weight, metabolic markers, and GI tolerance are standard of care.
The Broader Obesity Treatment Landscape
Obesity is now formally recognised as a chronic, relapsing disease by major medical organisations including the World Obesity Federation and the American Medical Association. This classification is consequential: it reframes weight gain not as a personal failure but as a condition with genetic, hormonal, environmental, and social drivers that often require sustained medical management.
The emergence of high-efficacy GLP-1 medications is shifting treatment paradigms that were, for decades, dominated by low-calorie diets and behavioural programmes that delivered modest, often temporary results. Combined with improving access frameworks—like the NICE TA875 pathway in England—semaglutide is poised to become a first-line pharmacological option in integrated obesity care.
Bottom Line
The OASIS 1 trial, published in The Lancet on August 26, 2023, delivers the clearest evidence yet that oral semaglutide 50 mg is a powerful addition to the obesity treatment toolkit. A 15.1% mean weight reduction over 68 weeks, with more than half of participants losing at least 15% of their body weight, places this oral formulation in the same efficacy tier as injectable GLP-1 agents. Combined with NICE's 2023 access guidance expanding NHS availability, semaglutide is moving from clinical trial headlines to real-world prescriptions—offering genuine hope to millions who have struggled to manage their weight despite sustained effort.
Always consult a qualified healthcare professional before starting, stopping, or changing any prescription medication.
Sources referenced
- Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial — The Lancet (https://doi.org/10.1016/s0140-6736(23)01185-6) informed this article's reporting and source checks.
